Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.
| Author | |
|---|---|
| Abstract |
:
Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis. |
| Year of Publication |
:
0
|
| Journal |
:
PloS one
|
| Volume |
:
13
|
| Issue |
:
1
|
| Number of Pages |
:
e0190999
|
| Date Published |
:
2018
|
| URL |
:
http://dx.plos.org/10.1371/journal.pone.0190999
|
| DOI |
:
10.1371/journal.pone.0190999
|
| Short Title |
:
PLoS One
|
| Download citation |
